ATNF - 180 Life Sciences Corp. Stock Price and Quote

ATNF [NASD]

Index	-	P/E	-	EPS (ttm)	-7.72	Insider Own	0.70%	Shs Outstand	2.24M	Perf Week	-1.79%
Market Cap	8.25M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.41M	Perf Month	98.80%
Income	-15.90M	PEG	-	EPS next Q	0.20	Inst Own	15.30%	Short Float / Ratio	38.10% / 0.13	Perf Quarter	-63.37%
Sales	-	P/S	-	EPS this Y	2.00%	Inst Trans	-	Short Interest	0.54M	Perf Half Y	-84.86%
Book/sh	13.31	P/B	0.25	EPS next Y	-	ROA	-30.40%	Target Price	80.00	Perf Year	-93.55%
Cash/sh	1.44	P/C	2.29	EPS next 5Y	-	ROE	-42.80%	52W Range	1.18 - 71.40	Perf YTD	-2.65%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-95.38%	Beta	0.67
Dividend %	-	Quick Ratio	1.40	Sales past 5Y	-	Gross Margin	-	52W Low	179.66%	ATR	1.04
Employees	7	Current Ratio	1.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	44.32	Volatility	25.83% 31.76%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-201.00%	Profit Margin	-	Rel Volume	0.08	Prev Close	3.24
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	4.28M	Price	3.30
Recom	2.50	SMA20	-14.72%	SMA50	-37.59%	SMA200	-80.28%	Volume	357,648	Change	1.85%

Sep-15-21

Initiated

Maxim Group

Buy

$11

Jan-25-23 08:45AM	180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytrens Disease GlobeNewswire +33.75%
Jan-17-23 08:00AM	180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom GlobeNewswire
Jan-05-23 08:30AM	180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire +12.33%
Jan-04-23 08:30AM	180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytrens Disease GlobeNewswire -17.36%
Dec-29-22 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders GlobeNewswire +13.86%
08:00AM	Loading…
Dec-23-22 08:00AM	180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire -21.52%
Dec-20-22 02:11PM	180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire -15.85%
Dec-16-22 09:00AM	180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan GlobeNewswire -11.67%
Nov-30-22 05:00PM	180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytrens Contracture GlobeNewswire
Nov-21-22 08:30AM	180 Life Sciences to Participate in A.G.P.s Virtual Biotech Conference to be Held November 30 December 1, 2022 GlobeNewswire -12.87%
Nov-15-22 12:37PM	CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytrens Disease GlobeNewswire +12.02%
08:00AM	Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytrens Disease GlobeNewswire
Sep-26-22 08:30AM	180 Life Sciences Issues Letter to Stockholders GlobeNewswire
Aug-22-22 08:30AM	180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder GlobeNewswire -10.53%
Jul-27-22 08:30AM	180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp. GlobeNewswire
08:00AM	Loading…
Jul-21-22 08:00AM	180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering GlobeNewswire +5.65%
Jul-18-22 08:30AM	180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering GlobeNewswire
Jun-22-22 04:05PM	180 Life Sciences Corp. Issues Letter to Stockholders GlobeNewswire
Jun-14-22 04:15PM	180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytrens Disease GlobeNewswire
May-31-22 08:30AM	180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytrens Disease GlobeNewswire +18.25%
May-02-22 08:00AM	REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytrens Disease Study Results in The Lancet Rheumatology GlobeNewswire -20.75%
Apr-29-22 06:32PM	180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytrens Disease Study Results in The Lancet Rheumatology GlobeNewswire +22.54%
Feb-17-22 08:30AM	180 Life Sciences Corp. Forms Scientific Advisory Board GlobeNewswire -6.61%
Jan-31-22 08:00AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders GlobeNewswire +7.12%
Dec-28-21 11:00AM	180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022 GlobeNewswire -5.75%
Dec-15-21 08:15AM	180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases GlobeNewswire
Dec-12-21 06:06AM	Insider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More Shares Simply Wall St.
Dec-10-21 05:15PM	180 Life Sciences Corp (ATNF) CEO James N. Woody Bought $53,375 of Shares GuruFocus.com
Dec-06-21 08:15AM	180 Life Sciences Provides Follow-Up Information on Oxford University and the Companys Successful Dupuytrens Phase 2b Clinical Trial Results GlobeNewswire +7.95%
Dec-01-21 02:45PM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial GlobeNewswire -20.85%
02:26PM	Loading…
02:26PM	180 Life Sciences: Positive Data From Dupuytrens Disease Study Could Be a Big Catalyst, Says Analyst TipRanks
Nov-22-21 08:30AM	180 Life Sciences Corp. Expands Patent Portfolio GlobeNewswire
Nov-18-21 08:15AM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium GlobeNewswire +9.86%
Nov-03-21 12:06PM	180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer GlobeNewswire
Oct-26-21 08:30AM	180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules GlobeNewswire
Sep-30-21 08:30AM	180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio GlobeNewswire +5.66%
Sep-20-21 08:00AM	Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications GlobeNewswire -6.29%
Aug-30-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders GlobeNewswire
Aug-24-21 08:30AM	180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement GlobeNewswire
Aug-19-21 09:00AM	180 Life Sciences Corp. Announces $15.0 Million Private Placement GlobeNewswire -25.73%
08:10AM	Is 180 Life Sciences Corp.'s (NASDAQ:ATNF) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Aug-02-21 08:00AM	Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021 GlobeNewswire
Jul-29-21 08:00AM	180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference GlobeNewswire
Jul-28-21 08:15AM	180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue GlobeNewswire
Jul-20-21 08:00AM	180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) GlobeNewswire
Jul-12-21 09:51AM	180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2) GlobeNewswire +9.75%
Jul-07-21 08:00AM	180 Life Sciences Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal GlobeNewswire
Jun-28-21 08:15AM	180 Life Sciences Joins Russell Microcap® Index GlobeNewswire
08:00AM	180 Life Sciences Files Plan with Nasdaq Related to Delayed Quarterly Report on Form 10-Q and Form 10-K GlobeNewswire
Jun-10-21 09:12AM	180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors GlobeNewswire
Jun-01-21 08:00AM	180 Life Sciences Corp. to Present at LD Micro Invitational XI GlobeNewswire +8.90%
May-28-21 08:00AM	180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors GlobeNewswire +7.96%
May-21-21 04:45PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report on Form 10-Q GlobeNewswire +10.61%
Apr-20-21 08:00AM	180 Life Sciences Corp. Announces Collection of All Patient Data for Phase 2b Dupuytrens Disease Trial GlobeNewswire
Apr-19-21 05:00PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Annual Report on Form 10-K GlobeNewswire -16.53%
Apr-14-21 08:15AM	180 Life Sciences Corp. Congratulates Dr. Lynn Williams on International Dupuytren Award 2021 GlobeNewswire
Mar-26-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics GlobeNewswire +18.57%
Mar-25-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters GlobeNewswire +13.65%
Mar-24-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders GlobeNewswire
Mar-08-21 01:30PM	180 Life Sciences Corp. to Present at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC GlobeNewswire +5.46%
Feb-24-21 04:00PM	180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement GlobeNewswire +11.06%
Feb-19-21 09:00AM	180 Life Sciences Corp. Announces $11.7 Million Private Placement GlobeNewswire -13.46%
Feb-17-21 12:00AM	Do Insiders Own Lots Of Shares In 180 Life Sciences Corp. (NASDAQ:ATNF)? Simply Wall St. -5.45%
Jan-11-21 08:00AM	180 Life Sciences Corp. to Present at the Biotech Showcase(TM) Digital 2021 Conference Newsfile +5.06%
Jan-05-21 02:50PM	180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference GlobeNewswire +7.17%
Dec-03-20 11:08AM	180 Life Sciences Corp. to Present at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15th at 1:40 PM EST GlobeNewswire
Nov-24-20 10:00AM	180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020 GlobeNewswire -6.93%
Nov-23-20 08:30AM	180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants GlobeNewswire +17.44%
Nov-17-20 08:00AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders GlobeNewswire
Nov-10-20 11:46AM	180 Life Sciences Announces Completion of Transaction with KBLM Merger Corp IV GlobeNewswire -6.47%

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience